HTLV-3 is a recently discovered human retrovirus, first identified in 2005 in Cameroon, that belongs to an entirely different branch of the retrovirus family than HIV-1. The name creates confusion because in the early 1980s, HIV-1 itself was briefly called “HTLV-III” before scientists recognized it as a fundamentally different kind of virus. Today’s HTLV-3 is a genuine member of the human T-lymphotropic virus group, closely related to a monkey virus called STLV-3, and it has been found in only a handful of people living in Central Africa.
Why the Same Name Was Used Twice
In 1984, Robert Gallo’s laboratory at the National Institutes of Health announced the isolation of a retrovirus from AIDS patients and named it HTLV-III, treating it as a third member of the human T-lymphotropic virus family after HTLV-1 and HTLV-2. Around the same time, Luc Montagnier’s team at the Pasteur Institute had isolated what they called LAV (lymphadenopathy-associated virus). Both groups were looking at the same virus, and by 1986 an international committee settled on a new name: Human Immunodeficiency Virus, or HIV. The renaming happened because researchers realized HIV was a lentivirus, not a deltaretrovirus like the original HTLVs. Lentiviruses and deltaretroviruses are as different from each other as cats are from dogs, even though both are retroviruses that insert their genetic material into the host’s DNA.
That left “HTLV-3” as an unused slot. When researchers in 2005 genuinely found a third human T-lymphotropic virus, they gave it the name HTLV-3. This creates an unfortunate situation where older medical literature referring to “HTLV-III” means HIV-1, while newer literature referring to “HTLV-3” means a completely different and far rarer virus. If you encounter the term in a paper or clinical report, the date and context usually clear things up: anything before about 1986 calling a virus HTLV-III is talking about HIV.
How HTLV-3 Was Found
The modern HTLV-3 was discovered independently by two research teams in 2005, both working with blood samples from people in Cameroon. One team screened 240 Cameroonian plasma samples for HTLV antibodies and found 48 that tested positive by one method but 27 of those gave ambiguous results on a more specific test. Using genetic amplification techniques targeting conserved regions of the virus, they identified a new retrovirus in a sample from a 62-year-old Bakola Pygmy man living in a remote rainforest settlement in southern Cameroon. Genetic analysis of two viral regions showed the virus was closely related to STLV-3, its simian counterpart, and the team tentatively named it HTLV-3.1PubMed Central. Discovery of a new human T-cell lymphotropic virus (HTLV-3) in Central Africa
The other team, working separately, found HTLV-3 infection among Central Africans who reported direct contact with nonhuman primate blood and body fluids through hunting, butchering, or keeping primate pets. Their phylogenetic analysis placed the new virus squarely within the diversity of STLV-3, a group of simian viruses never before seen in humans.2PubMed Central. Emergence of unique primate T-lymphotropic viruses among central African bushmeat hunters That same team also discovered HTLV-4, a virus sitting on a phylogenetic branch distinct from all known HTLVs and STLVs, making Cameroon’s forests something of a hotspot for retroviral spillover.
How HTLV-3 and HIV-1 Differ at a Fundamental Level
Despite both being retroviruses, HTLV-3 and HIV-1 belong to different genera and use radically different strategies to persist in the body. HIV-1 is a lentivirus. It replicates aggressively by producing enormous numbers of new virus particles that infect fresh cells. This is why untreated HIV infection drives a steep, measurable decline in CD4+ T cells over time, eventually leading to AIDS.
HTLV-3, like HTLV-1 and HTLV-2, is a deltaretrovirus. Deltaretroviruses take a quieter approach: instead of churning out free-floating virus, they replicate mainly by forcing the infected cell itself to divide, copying their DNA along with the cell’s own genome each time.3PubMed Central. Different Mutation Tolerance of Lentiviral (HIV-1) and Deltaretroviral (BLV and HTLV) Protease Precursors This cell-division strategy means the virus accumulates slowly and often without obvious symptoms for years or even decades. It also means the virus mutates far more slowly than HIV, since it avoids the error-prone step of reverse transcription every replication cycle.
This fundamental difference in replication style explains why HIV and HTLV cause such different diseases. HIV burns through the immune system. HTLV-1, the best-studied member of the HTLV family, can eventually drive certain infected T cells to become cancerous, leading to adult T-cell leukemia/lymphoma in a small percentage of carriers, or cause a progressive neurological condition. Whether HTLV-3 follows the same disease pattern remains unknown.
What Makes HTLV-3 Biologically Distinctive
Even within the HTLV family, HTLV-3 has some unique characteristics. When researchers sequenced the complete genome of the first HTLV-3 isolate (designated Pyl43), they found the expected retroviral toolkit of gag, pol, env, tax, and rex genes. But its long terminal repeat region, which helps control viral gene expression, contained only two Tax-responsive elements, matching STLV-3 rather than the three found in HTLV-1. More unexpectedly, a 366-base-pair stretch in the regulatory region was missing compared to STLV-3, eliminating a sequence called RorfII entirely.4PubMed Central. Human T-cell lymphotropic virus type 3: complete nucleotide sequence and characterization of the human tax3 protein What that deletion means for how the virus behaves in human cells is still an open question.
The virus also shows a distinctive pattern in how it attaches to and enters cells. HTLV-1 primarily binds to activated CD4+ T cells, and HTLV-2 primarily binds to activated CD8+ T cells. HTLV-3 binds efficiently to both. Perhaps more striking, HTLV-3 can also bind to naive CD4+ T cells, which neither HTLV-1 nor HTLV-2 can latch onto. This is because HTLV-3 does not depend on the same set of helper molecules on the cell surface that HTLV-1 needs. HTLV-1 relies heavily on heparan sulfate proteoglycans and neuropilin-1 to get a foothold, but HTLV-3 can bind efficiently even when those molecules are absent.5PubMed Central. The receptor complex associated with human T-cell lymphotropic virus type 3 (HTLV-3) Env-mediated binding and entry is distinct from, but overlaps with, the receptor complexes of HTLV-1 and HTLV-2 The broader cell tropism could theoretically mean HTLV-3 has access to a wider range of immune cells, but with so few infected individuals ever studied, nobody knows whether that translates into different clinical outcomes.
Does HTLV-3 Cause Disease?
So far, no disease has been linked to HTLV-3 infection. Every person identified as carrying the virus has been asymptomatic at the time of testing. That observation comes with an enormous caveat: the total number of known HTLV-3-positive individuals can be counted on one hand, and HTLV-related diseases in general take decades to develop. HTLV-1 causes leukemia or neurological disease in only about 5 to 10 percent of carriers, often after 20 or more years of silent infection. With HTLV-3 so newly recognized and so rarely detected, absence of disease could easily reflect the small sample size rather than true harmlessness.
Laboratory work adds a reason for caution. When researchers compared the Tax protein of HTLV-3 (called Tax-3) with those of HTLV-1 and HTLV-2, they found that Tax-3 behaved much more like Tax-1 than Tax-2 in terms of how it activated gene transcription in both T cells and other cell types. Since Tax-1 is considered the key driver of HTLV-1’s ability to transform cells into cancer, the functional similarity raises the possibility that HTLV-3 could share some of HTLV-1’s potential to cause leukemia.6PubMed Central. The transcription profile of Tax-3 is more similar to Tax-1 than Tax-2: insights into HTLV-3 potential leukemogenic properties That is still speculative, and no case of HTLV-3-associated cancer has ever been reported.
How Rare Is HTLV-3?
Extremely rare, as far as anyone can tell. By 2010, researchers had documented only four confirmed HTLV-3 infections, all in people living in Cameroon.7PubMed Central. Emergence of a novel and highly divergent HTLV-3 in a primate hunter in Cameroon A review of available evidence noted that these cases, combined with the wide distribution of STLV-3 in African monkey species, suggest the virus is not vanishingly rare in Central African populations with primate exposure, but it remains undetected elsewhere.8PubMed Central. HTLV-3/STLV-3 and HTLV-4 viruses: discovery, epidemiology, serology and molecular aspects
Part of the challenge is detection. Standard blood bank screening tests are designed to catch HTLV-1 and HTLV-2. When a large cross-sectional study of over 220,000 blood donors in São Paulo, Brazil, included a specific test for HTLV-3, no cases were found.9Wiley Online Library. HTLV screening and confirmatory testing among blood donors in São Paulo: A cross-sectional study That result is not surprising given that all known HTLV-3 cases come from Central Africa, but it illustrates how little systematic screening has been done in the populations where the virus is most likely to exist. HTLV-3 infections may produce ambiguous or “indeterminate” results on standard HTLV-1/2 tests, meaning carriers could easily be missed or misclassified without additional molecular testing.
The broader picture is one of neglect. A 2025 review described HTLV-3 and HTLV-4 as “poorly characterized” and noted that they are genetically close to their simian counterparts, consistent with recent zoonotic transmission events. The review called for increased awareness and research investment, noting that the long latency period of HTLV infections and the lack of effective treatments make public health responses especially difficult.10PubMed Central. Human T-Lymphotropic Virus (HTLV): Epidemiology, Genetic, Pathogenesis, and Future Challenges
Zoonotic Origins and the Primate Connection
Every known HTLV-3 infection appears to trace back to contact with nonhuman primates. The virus is the human counterpart of STLV-3, which circulates in multiple monkey species across West, Central, and East Africa. The genetic evidence points not to a single spillover event but to multiple independent transmissions from different primate species to humans over time. The fourth confirmed case of HTLV-3, for example, carried a viral strain sharing 98 percent genetic identity with an STLV-3 subtype found in guenon monkeys living near the infected person’s village.7PubMed Central. Emergence of a novel and highly divergent HTLV-3 in a primate hunter in Cameroon This pattern of local, repeated zoonotic jumps mirrors what researchers believe happened with HTLV-1 and HTLV-2, which also have simian counterparts and appear to have crossed into humans multiple times throughout history.
The evolutionary timescales involved are staggering. Full-genome analyses of the broader primate T-lymphotropic virus family estimate that the common ancestor of all PTLVs existed at least 1.3 million years ago. HTLV-1 subtypes diverged from their simian ancestors over roughly 19,500 years, while the split between HTLV-2 and STLV-2 may go back 400,000 years.11Molecular Biology and Evolution. Tempo and Mode of Human and Simian T-Lymphotropic Virus (HTLV/STLV) Evolution Revealed by Analyses of Full-Genome Sequences The STLV-3 lineage that gave rise to HTLV-3 shows substantial internal diversity. Different STLV-3 subtypes can be as genetically distant from each other as HTLV-1 subtypes are from one another, suggesting the lineage has been evolving independently for a very long time.12PubMed Central. Complete sequence of a novel highly divergent simian T-cell lymphotropic virus from wild-caught red-capped mangabeys (Cercocebus torquatus) from Cameroon: a new primate T-lymphotropic virus type 3 subtype
All of this means that the HTLV-3 we know today likely represents just a glimpse of a much larger pool of related viruses circulating in African primates. Future surveillance might well uncover additional subtypes and strains crossing into human populations, especially in regions where bushmeat hunting remains common.
What Happens When HIV-1 and HTLV Infect the Same Person
While HTLV-3 co-infection with HIV-1 has never been documented (given how few HTLV-3 cases exist), the much better-studied interaction between HIV-1 and HTLV-1 offers a sobering preview of how retroviruses with opposing strategies can complicate each other’s effects. A systematic review of clinical and laboratory outcomes in people co-infected with both HIV-1 and HTLV-1 found that co-infected patients had shorter survival and faster progression to death compared to people infected with either virus alone. Paradoxically, co-infected individuals tended to have higher CD4+ cell counts, which might seem reassuring but reflects HTLV-1’s ability to drive T-cell proliferation rather than genuine immune health. Co-infected patients were also less likely to be on antiretroviral therapy and had substantially higher rates of skin conditions, fungal infections, parasitic disease, and neurological complications.13PubMed Central. Clinical and Laboratory Outcomes in HIV-1 and HTLV-1/2 Coinfection: A Systematic Review
The misleadingly elevated CD4 counts are particularly problematic because clinicians in resource-limited settings sometimes use CD4 thresholds to guide treatment decisions. A patient co-infected with HIV-1 and HTLV-1 might appear to be doing better immunologically than they actually are, delaying the initiation of treatment they need. Whether HTLV-3, with its broader cell tropism and its ability to bind both CD4+ and CD8+ T cells, would create similar or different dynamics in a co-infection scenario is completely unknown.
The Diagnostic Blind Spot
One of the most practically important things about HTLV-3 is how easy it is to miss. Current screening assays used in blood banks and clinical laboratories worldwide are designed to detect antibodies against HTLV-1 and HTLV-2. HTLV-3 is related enough that it sometimes triggers a weakly positive result on these tests, but the confirmatory tests that follow are not equipped to identify it as a distinct virus. This is exactly how the first HTLV-3 cases were found: they showed up as indeterminate serologies, neither cleanly positive for HTLV-1 or HTLV-2 nor cleanly negative, prompting researchers to dig deeper with molecular tools.8PubMed Central. HTLV-3/STLV-3 and HTLV-4 viruses: discovery, epidemiology, serology and molecular aspects
In routine clinical practice, an indeterminate HTLV result is typically followed up with a lineage-specific test that can distinguish HTLV-1 from HTLV-2. If neither is confirmed, the sample is usually classified as a false positive or left in an unresolved category. Without specific HTLV-3 molecular assays, an actual HTLV-3 infection would fall into that unresolved bin. This raises the uncomfortable possibility that HTLV-3 infections outside Central Africa, or even within it, are going unrecognized. The virus could be circulating at low levels in populations that have contact with African primates or with travelers from endemic regions, and current testing infrastructure would simply not pick it up.
Developing and deploying HTLV-3-specific diagnostics is not straightforward. The virus is so rare that the commercial incentive to create targeted assays is minimal. Public health justification for expanded screening depends on understanding the virus’s disease potential, but understanding its disease potential requires finding more infected individuals, which requires better diagnostics. It is a classic chicken-and-egg problem in neglected tropical virology, and for now, HTLV-3 remains stuck in it.